Clinical Trial Update: Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 open-label dose-escalation trial to assess the safety of a single intravitreal injection of RTx-021 in patients with Stargardt disease, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• RTx-021

Snippet

Sponsor: Ray Therapeutics, Inc. | Conditions: Stargardt Disease | Phase 1, Phase 2 | Status: RECRUITING